CAMBRIDGE, MA – September 25, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company, announced its participation in the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO), taking place October 17-21 in Berlin, Germany.
The company will present exciting Phase 1 clinical data on two immuno-oncology programs: the first-in-class anti-TNFR2 agonist emunkitug, and an anti-BTLA antagonist with best-in-class potential, HFB200603. The posters will report updated safety and efficacy results along with potential predictive biomarkers of clinical benefit.
HiFiBiO’s novel immunotherapies powered by AI/ML and its single-cell translational platform demonstrate the company’s deep commitment to the development of impactful therapies to address unmet medical needs.
Details of the poster presentation are as follows:
Presentation # 994P
Title: Potential Predictive Biomarkers of Clinical Benefit from Emunkitug (HFB200301) in Combination with Tislelizumab: Integrated Analysis of Tumor, Peripheral Blood, and Patient Treatment History.
Session Date: Sunday, October 19, 2025
Session Time: 12:00 – 12:45 CEST
Speaker: Desamparados Roda, MD, PhD, Hospital Clínico de Valencia
Presentation # 949P
Title: Evaluation of HVEM and PD-L1 Expression Profile in Tumors as Potential Predictive Biomarkers for HFB200603, a BTLA antagonist, as Monotherapy and in Combination with Tislelizumab.
Session Date: Sunday, October 19, 2025
Session Time: 12:00 – 12:45 CEST
Speaker: María de Miguel, MD, PhD, Hospital Universitario HM Sanchinarro
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage biotech pioneering curative immunotherapies for patients with unmet medical needs. The company is targeting the root cause of disease through its unique Drug Intelligence Science (DIS®) platform. DIS® enables a deep understanding of cellular and molecular pathology across various diseases through proprietary single cell technology and AI/ML analytics. This platform is being deployed in target discovery, antibody selection, and predictive biomarker identification to achieve enhanced clinical success for patients. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized globally for its innovative drug development capabilities. For additional information, please visit www.hifibio.com
HiFiBiO® is a trademark of HiFiBiO Therapeutics and its affiliates